Literature DB >> 11115021

Receipt of psychotropic medication by people with intellectual disability in residential settings.

J Robertson1, E Emerson, N Gregory, C Hatton, S Kessissoglou, A Hallam.   

Abstract

Previous studies have reported that the rate of prescription of antipsychotic medication for people with intellectual disability is far in excess of the expected prevalence of psychoses for this population. Recent research identifying factors which predict the use of psychotropic medication suggests that challenging behaviour may play a key role in determining the receipt of antipsychotic medication. The present study reports the prevalence of psychoactive medication receipt for 500 people with intellectual disability living in different forms of residential provision in the UK. Variables which predict the receipt of psychotropic medication are also identified. The results show differences between forms of residential provision in rates of medication receipt. Analyses of predictors of psychotropic medication receipt suggest that, whilst the receipt of antidepressants is predicted by symptoms of mental ill health, the receipt of both antipsychotics and hypnotics/anxiolytics is predicted by variables related to challenging behaviour.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11115021     DOI: 10.1046/j.1365-2788.2000.00307.x

Source DB:  PubMed          Journal:  J Intellect Disabil Res        ISSN: 0964-2633


  22 in total

1.  The prevalence and incidence of mental ill-health in adults with autism and intellectual disabilities.

Authors:  Craig A Melville; Sally-Ann Cooper; Jill Morrison; Elita Smiley; Linda Allan; Alison Jackson; Janet Finlayson; Dipali Mantry
Journal:  J Autism Dev Disord       Date:  2008-02-29

Review 2.  Medication use and potentially inappropriate prescribing in older adults with intellectual disabilities: a neglected area of research.

Authors:  Maire O'Dwyer; Philip McCallion; Mary McCarron; Martin Henman
Journal:  Ther Adv Drug Saf       Date:  2018-06-20

3.  The association between repetitive, self-injurious and aggressive behavior in children with severe intellectual disability.

Authors:  Chris Oliver; Jane Petty; Loraine Ruddick; Monique Bacarese-Hamilton
Journal:  J Autism Dev Disord       Date:  2012-06

4.  Prevalence of psychotropic drug use in adults with intellectual disability: positive and negative findings from a large scale study.

Authors:  John A Tsiouris; Soh-Yule Kim; W Ted Brown; Jill Pettinger; Ira L Cohen
Journal:  J Autism Dev Disord       Date:  2013-03

Review 5.  Pharmacists' medicines-related interventions for people with intellectual disabilities: a narrative review.

Authors:  Máire O'Dwyer; Arijana Meštrović; Martin Henman
Journal:  Int J Clin Pharm       Date:  2015-04-24

6.  Drug burden index to define the burden of medicines in older adults with intellectual disabilities: An observational cross-sectional study.

Authors:  Juliette O'Connell; Éilish Burke; Niamh Mulryan; Claire O'Dwyer; Clare Donegan; Philip McCallion; Mary McCarron; Martin C Henman; Máire O'Dwyer
Journal:  Br J Clin Pharmacol       Date:  2018-01-05       Impact factor: 4.335

7.  Chronicity of challenging behaviours in people with severe intellectual disabilities and/or autism: a total population sample.

Authors:  Glynis H Murphy; Julie Beadle-Brown; Lorna Wing; Judy Gould; Amitta Shah; Nan Holmes
Journal:  J Autism Dev Disord       Date:  2005-08

8.  Dual Diagnosis: A Problematic Construct When Applied to Persons with Intellectual Disabilities.

Authors:  John D McLennan
Journal:  Can J Psychiatry       Date:  2018-04-19       Impact factor: 4.356

9.  Inter-Rater Reliability of the Diagnoses of Psychosis and Depression in Individuals with Intellectual Disabilities.

Authors:  S Einfeld; B Tonge; L Chapman; C Mohr; J Taffe; S Horstead
Journal:  J Appl Res Intellect Disabil       Date:  2007-09

Review 10.  Diagnosis and treatment of aggression in individuals with developmental disabilities.

Authors:  Diana J Antonacci; Crystal Manuel; Ervin Davis
Journal:  Psychiatr Q       Date:  2008-08-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.